Skip to main content
Immunovia logo

Immunovia — Investor Relations & Filings

Ticker · IMMNOV ISIN · SE0006091997 LEI · 549300KHWL6KK1XGUO81 ST Human health and social work activities
Open in API
Filings indexed 377 across all filing types
Latest filing 2026-05-22 Major Shareholding Noti…
Country SE Sweden
Listing ST IMMNOV

About Immunovia

https://immunovia.com/

Immunovia is a diagnostics company focused on revolutionizing the early detection of pancreatic cancer. Its primary product is the PancreaSure test, a simple blood test designed to detect pancreatic cancer at Stage 1 and 2 with high accuracy. The test is intended for annual surveillance of individuals at elevated risk due to family history or genetic mutations. PancreaSure functions by detecting proteins and other biomarkers indicative of pancreatic cancer growth. The company's mission is to improve survival rates for this highly lethal cancer by enabling diagnosis at its earliest, most treatable stages, offering a convenient alternative to invasive imaging procedures.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2026
Major Shareholding Notification Classification · 87% confidence The document is a notification from the Swedish Financial Supervisory Authority (Finansinspektionen) disclosing that Avanza Bank Holding AB, on behalf of Försäkringsaktiebolaget Avanza Pension, has crossed a 10% shareholding threshold in Immunovia AB. This is a classic major shareholding notification under Chapter 4 of the Swedish Securities Market Act (LHF). It is not a general earnings release or management report; it specifically reports change in significant share ownership levels.
2026-05-22 Swedish
KOMMUNIKÉ FRÅN ÅRSSTÄMMA DEN 13 MAJ 2026 I IMMUNOVIA AB (PUBL)
Declaration of Voting Results & Voting Rights Announcements Classification · 85% confidence The document is a press release summarizing the resolutions passed at Immunovia AB’s Annual General Meeting held on 13 May 2026, including approval of the financial statements, discharge of board and CEO, election and remuneration of board and auditor, authorization for share issues, and approval of option programs. It is not a full annual report, management presentation, or legal notice, but rather an official report of the voting outcomes and decisions from the AGM. This matches the “Declaration of Voting Results & Voting Rights Announcements” category.
2026-05-13 Swedish
BULLETIN FROM THE ANNUAL GENERAL MEETING ON 13 MAY 2026 IN IMMUNOVIA AB (PUBL)
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a press release summarizing the resolutions adopted at Immunovia AB’s Annual General Meeting on 13 May 2026, including vote outcomes on accounts, board elections, authorizations, and option programs. It provides the official results of shareholder votes, indicating a declaration of voting results rather than the full AGM materials, financial statements, or pre-meeting proxy solicitation. Hence, it best fits the Declaration of Voting Results & Voting Rights Announcements category (DVA).
2026-05-13 English
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport Januari-mars 2026' which translates to 'Interim Report January-March 2026'. It contains detailed financial data including net revenue, operating results, cash flow, equity, and other financial metrics for the first quarter of 2026. The text includes management commentary (CEO letter), key events during the quarter, and detailed financial statements summaries. The length is about 15,000 characters, indicating a full report rather than a brief announcement. The content and structure clearly indicate this is a quarterly interim financial report with substantive financial data and analysis, not just an announcement or summary. Therefore, the correct classification is Interim / Quarterly Report (IR).
2026-05-07 English
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT January-March 2026' and contains detailed financial data, including net sales, operating results, earnings per share, cash flow, equity ratio, and number of shares for the first quarter of 2026. It includes a CEO comment, key performance indicators, and a comprehensive table of contents indicating financial statements and notes. The length is about 15,000 characters, indicating a full report rather than a brief announcement. The content is consistent with a quarterly financial report providing substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2026-05-07 English
Major Shareholding Notification 2026
Major Shareholding Notification Classification · 100% confidence The document is a notification from the Swedish Financial Supervisory Authority (Finansinspektionen) regarding a major shareholding transaction involving Immunovia AB. It details the acquisition of shares by Avanza Bank Holding AB for its subsidiary, including the number of shares held, voting rights percentages, and the date of the transaction. The document is structured as a regulatory disclosure of a significant change in share ownership, specifically a major shareholding notification. It does not contain financial statements, management commentary, or other report content. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length is 3383 characters, which is consistent with a notification rather than a full report.
2026-05-06 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.